Ustekinumab Biosimilar (qyuns)

乌司奴单抗生物类似药 (qyuns)

Report date: 2026/05/22 20:01:29

Base Information

Drug NameUstekinumab Biosimilar (qyuns)
Drug Alias Name乌司奴单抗生物仿制药 (qyuns)赛乐信赛捷宁QX-001SQX-001-S +[9] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-12 inhibitorsInterleukin-23 inhibitors
TargetsInterleukin-12Interleukin-23
Therapy Area/IndicationsPlaque psoriasisPsoriasisCrohn Disease
Global Approved IndicationsPlaque psoriasis
Approved Indications in ChinaPlaque psoriasis
Original Approved Country/TerritoryMainland China
Original Approved Date2024/10/29
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesQyuns Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesQyuns Therapeutics Co LtdHangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisCrohn Disease
Inactive IndicationsPsoriasis

Other Information

ATC CodeL04AC05
Related LinksN/A